High-dose lymphoablative therapy (HDLT) with or without autologous stem-cell rescue for treatment of severe autoimmune diseases. [electronic resource]
Producer: 20020412Description: 29-9 p. digitalSubject(s):- Antilymphocyte Serum -- administration & dosage
- Autoimmune Diseases -- mortality
- Blue Cross Blue Shield Insurance Plans
- Cyclophosphamide -- administration & dosage
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Immunosuppressive Agents -- administration & dosage
- Insurance Coverage
- Technology Assessment, Biomedical
- Transplantation, Autologous
- Treatment Outcome
- United States
- United States Food and Drug Administration
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.